PLN 92.8
(-1.28%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1.85 Million PLN | 72.88% |
2022 | 1.07 Million PLN | 325.72% |
2021 | 252.04 Thousand PLN | 1284.4% |
2020 | 18.2 Thousand PLN | -58.64% |
2019 | 44.02 Thousand PLN | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 1.8 Million PLN | -2.7% |
2024 Q2 | 2.65 Million PLN | 46.81% |
2023 Q1 | 1.02 Million PLN | -4.47% |
2023 Q4 | 1.85 Million PLN | 24.0% |
2023 Q3 | 1.49 Million PLN | 21.63% |
2023 Q2 | 1.23 Million PLN | 20.0% |
2023 FY | 1.85 Million PLN | 72.88% |
2022 Q1 | 158.38 Thousand PLN | -37.16% |
2022 Q4 | 1.07 Million PLN | 21.66% |
2022 Q3 | 882 Thousand PLN | -17.49% |
2022 Q2 | 1.06 Million PLN | 574.93% |
2022 FY | 1.07 Million PLN | 325.72% |
2021 Q1 | 615.24 Thousand PLN | 0.0% |
2021 FY | 252.04 Thousand PLN | 1284.4% |
2021 Q4 | 252.04 Thousand PLN | 421.74% |
2021 Q3 | 48.3 Thousand PLN | -14.32% |
2021 Q2 | 56.38 Thousand PLN | -90.84% |
2020 FY | 18.2 Thousand PLN | -58.64% |
2019 FY | 44.02 Thousand PLN | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Bioceltix S.A. | 2.26 Million PLN | 18.231% |
BIOTON S.A. | 215.86 Million PLN | 99.141% |
Captor Therapeutics Spolka Akcyjna | 28.07 Million PLN | 93.392% |
Mabion S.A. | 90.47 Million PLN | 97.95% |
Molecure S.A. | 11.34 Million PLN | 83.649% |
NanoGroup S.A. | 1.49 Million PLN | -24.489% |
Pharmena S.A. | 1.9 Million PLN | 2.676% |
Poltreg S.A. | 39.58 Million PLN | 95.313% |
Pure Biologics Spólka Akcyjna | 20.84 Million PLN | 91.101% |
Ryvu Therapeutics S.A. | 120.36 Million PLN | 98.459% |
Synthaverse S.A. | 153.26 Million PLN | 98.79% |